Servet Turgut
Research Subjects
Servet Turgut has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Emrah Uğuz
Department of Cardiovascular Surgery, Ankara Yıldırım Beyazıt University Faculty of Medicine, 06010 Ankara, Türkiye, Turkey (Türkiye)
2 shared publications - Erol Şener
Department of Cardiovascular Surgery, Ankara Yildirim Beyazit University, School of Medicine and Ankara Bilkent City Hospital, 06010 Ankara, Türkiye
2 shared publications - Kemal Eşref Erdoğan
Yildirim Beyazit University
2 shared publications - Muhammet Fethi Sağlam
Department of Cardiovascular Surgery, Ankara Yıldırım Beyazıt University Faculty of Medicine, 06010 Ankara, Türkiye, Turkey (Türkiye)
2 shared publications - Murat Yücel
Department of Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara 06800, Türkiye
2 shared publications - Abdulkadir Yılmaz
Department of Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4714
Morphometric Aortic Remodeling and Mid-Term Outcomes After TEVAR for Acute Stanford Type B Aortic Dissection: A Single-Center Retrospective Cohort Study
Objectives: This study aimed to evaluate the impact of thoracic endovascular aortic repair (TEVAR) on aortic remodeling using CT angiography-based morphometric measurements and to examine associated mid-term clinical outcomes in patients with acute Stanford type B aortic dissection. Methods: This retrospective, single-center observational cohort study included 33 consecutive patients who underwent TEVAR for acute Stanford type B aortic dissection between January 2020 and January 2025. Preoperative and postoperative true lumen (TL), false lumen (FL), and descending aorta (DA) diameters were compared using paired t-tests after Shapiro–Wilk normality testing. Endoleak, reintervention, FL thrombosis, and mortality were analyzed. Univariable analyses identified factors associated with endoleak and reintervention. Spearman’s correlation assessed factors associated with morphometric remodeling response. Results: All 33 patients had acute Stanford type B dissection (mean time to intervention: 2.73 ± 3.86 days). Among 33 patients (81.8% male; mean age 53.6 ± 12.1 years), mean follow-up was 4.08 ± 1.66 years. TEVAR induced a significant aortic remodeling response: TL diameter increased from 9.55 ± 5.91 mm to 28.30 ± 5.49 mm (+18.76 ± 8.83 mm; p < 0.001) and FL diameter decreased from 33.39 ± 6.76 mm to 11.48 ± 8.97 mm (−21.91 ± 9.53 mm; p < 0.001), while DA diameter remained stable (42.94 ± 6.90 vs. 42.03 ± 9.46 mm; p = 0.323). Complete FL thrombosis was achieved in 19 patients (57.6%). Endoleak occurred in nine patients (27.3%); Zone 2 landing was significantly associated with endoleak (54.5% vs. 13.6%, p = 0.033). Secondary intervention was required in 13 patients (39.4%). Overall mortality was 12.1%. Narrower preoperative TL was strongly associated with greater TL expansion (Spearman r = −0.724, p < 0.001); longer stent–graft coverage was associated with greater TL gain (r = +0.522, p = 0.002). Conclusions: TEVAR induced clinically meaningful aortic remodeling in acute Stanford type B dissection without progressive aortic enlargement. A narrower baseline TL and longer stent–graft coverage were associated with greater remodeling benefit. Zone 2 deployment was significantly associated with higher endoleak rates, underscoring the value of careful preprocedural planning and systematic long-term imaging surveillance.
- 17 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4714
Open AccessMorphometric Aortic Remodeling and Mid-Term Outcomes After TEVAR for Acute Stanford Type B Aortic Dissection: A Single-Center Retrospective Cohort Study
Objectives: This study aimed to evaluate the impact of thoracic endovascular aortic repair (TEVAR) on aortic remodeling using CT angiography-based morphometric measurements and to examine associated mid-term clinical outcomes in patients with acute Stanford type B aortic dissection. Methods: This retrospective, single-center observational cohort study included 33 consecutive patients who underwent TEVAR for acute Stanford type B aortic dissection between January 2020 and January 2025. Preoperative and postoperative true lumen (TL), false lumen (FL), and descending aorta (DA) diameters were compared using paired t-tests after Shapiro–Wilk normality testing. Endoleak, reintervention, FL thrombosis, and mortality were analyzed. Univariable analyses identified factors associated with endoleak and reintervention. Spearman’s correlation assessed factors associated with morphometric remodeling response. Results: All 33 patients had acute Stanford type B dissection (mean time to intervention: 2.73 ± 3.86 days). Among 33 patients (81.8% male; mean age 53.6 ± 12.1 years), mean follow-up was 4.08 ± 1.66 years. TEVAR induced a significant aortic remodeling response: TL diameter increased from 9.55 ± 5.91 mm to 28.30 ± 5.49 mm (+18.76 ± 8.83 mm; p < 0.001) and FL diameter decreased from 33.39 ± 6.76 mm to 11.48 ± 8.97 mm (−21.91 ± 9.53 mm; p < 0.001), while DA diameter remained stable (42.94 ± 6.90 vs. 42.03 ± 9.46 mm; p = 0.323). Complete FL thrombosis was achieved in 19 patients (57.6%). Endoleak occurred in nine patients (27.3%); Zone 2 landing was significantly associated with endoleak (54.5% vs. 13.6%, p = 0.033). Secondary intervention was required in 13 patients (39.4%). Overall mortality was 12.1%. Narrower preoperative TL was strongly associated with greater TL expansion (Spearman r = −0.724, p < 0.001); longer stent–graft coverage was associated with greater TL gain (r = +0.522, p = 0.002). Conclusions: TEVAR induced clinically meaningful aortic remodeling in acute Stanford type B dissection without progressive aortic enlargement. A narrower baseline TL and longer stent–graft coverage were associated with greater remodeling benefit. Zone 2 deployment was significantly associated with higher endoleak rates, underscoring the value of careful preprocedural planning and systematic long-term imaging surveillance.
- Open Access
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3419
De Ritis Ratio as an Independent Predictor of In-Hospital Mortality in Surgically Treated Acute Aortic Dissection
Background/Objectives: Every hour of delay in treating acute aortic dissection (AAD) increases mortality by 1–2%, underscoring the critical need for rapid identification of high-risk patients. Despite advances in surgical management, in-hospital mortality remains substantial, and early, reliable risk stratification tools are urgently needed. We targeted to assess the relationship between the De Ritis ratio (DRr) and in-hospital mortality in patients experiencing surgery for AAD. Methods: In this single-center retrospective study, 182 patients who underwent surgery for AAD between 2020 and 2025 were included. Demographic, clinical, laboratory, and echocardiographic data were analyzed. Receiver operating characteristic analysis was used to estimate the DRr’s discriminatory ability, and univariable and multivariable logistic regression analyses were utilized to find predictors of in-hospital mortality. Results: In-hospital mortality occurred in 59 patients (32.4%). When comparing survivors to non-survivors, the DRr was noticeably greater. Along with age, lactate level, and ejection fraction, the DRr continued to be an independent predictor of in-hospital mortality in multivariable analysis. Receiver operating characteristic analysis showed moderate discriminatory performance of the DRr, with an area under the curve of 0.701 and an optimal cut-off value of 1.308. Conclusions: The DRr is a practical and accessible biomarker related to in-hospital mortality in surgically treated AAD and may provide incremental prognostic value when used alongside established clinical and laboratory parameters.
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3419
Open AccessDe Ritis Ratio as an Independent Predictor of In-Hospital Mortality in Surgically Treated Acute Aortic Dissection
Background/Objectives: Every hour of delay in treating acute aortic dissection (AAD) increases mortality by 1–2%, underscoring the critical need for rapid identification of high-risk patients. Despite advances in surgical management, in-hospital mortality remains substantial, and early, reliable risk stratification tools are urgently needed. We targeted to assess the relationship between the De Ritis ratio (DRr) and in-hospital mortality in patients experiencing surgery for AAD. Methods: In this single-center retrospective study, 182 patients who underwent surgery for AAD between 2020 and 2025 were included. Demographic, clinical, laboratory, and echocardiographic data were analyzed. Receiver operating characteristic analysis was used to estimate the DRr’s discriminatory ability, and univariable and multivariable logistic regression analyses were utilized to find predictors of in-hospital mortality. Results: In-hospital mortality occurred in 59 patients (32.4%). When comparing survivors to non-survivors, the DRr was noticeably greater. Along with age, lactate level, and ejection fraction, the DRr continued to be an independent predictor of in-hospital mortality in multivariable analysis. Receiver operating characteristic analysis showed moderate discriminatory performance of the DRr, with an area under the curve of 0.701 and an optimal cut-off value of 1.308. Conclusions: The DRr is a practical and accessible biomarker related to in-hospital mortality in surgically treated AAD and may provide incremental prognostic value when used alongside established clinical and laboratory parameters.
- Open Access
- 31 December 2022
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 32 (6) , 719-723
Kalp Nakli Sonrası Dekompanze Kalp Yetmezliğine Neden Olan Akut Rejeksiyonda Plazmaferezin Rolü
Background/Aims: In this study, the results of patients who had orthotopic heart transplantation (OHT) in acute rejection who admitted to our clinic with decompensated heart failure and who could not undergo endomyocardial biopsy (EMB) were evaluated. Methods: The study included 27 patients who underwent OHT in our clinic between December 1998 and November 2021, who admitted with acute rejection causing decompensated heart failure during follow-up, and who could not undergo EMB and administered IV pulse steroid plus plasmapheresis. Demographics of patients, peri-treatment left ventricular functions, survival rates and causes of mortality were analyzed. Results: 19 (70.4%) were male and mean age was 28.7 ± 14.7 (range: 3-54). After OHT, overall survival rates were 92.6%, 77.6%, and 69.4% at 1st, 3rd and 5th year respectively. During the follow-up, the survival rates of patients who presented with decompensated heart failure and given pulse steroid plus plasmapheresis were 70.4%, 58.8%, and 53.4% at 1st, 3rd and 5th year respectively after plasmapheresis. Median rejection time after transplant was 19 months (range 0-113 months). Pre-, and post-treatment left ventricle ejection fractions were 25.11% ± 11.1%, and 52.14% ± 13.4% respectively (p<0.05). The leading causes of mortality were pneumonia causing sepsis (5/13 patients). Conclusions: In acute rejection patients with decompensated heart failure in whom EMB is not possible, administration of plasmapheresis in addition to IV pulse steroid therapy may have a positive effect on survival in this patient group. Özet Amaç: Bu çalışmada ortotopik kalp nakli (OHT) yapılan, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile kliniğimize başvuran ve endomiyokardiyal biyopsi (EMB) yapılamayan hastaların sonuçları değerlendirildi. Yöntemler: Çalışmaya Aralık 1998-Kasım 2021 tarihleri arasında kliniğimizde OHT yapılıp, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile başvuran ve EMB uygulanamayan, IV pulse steroid + plazmaferez uygulanan 27 hasta dahil edildi. Hastaların demografik özellikleri, tedavi öncesi sol ventrikül fonksiyonları, sağkalım oranları ve mortalite nedenleri analiz edildi. Bulgular: Hastaların 19'u (%70.4) erkekti ve yaş ortalaması 28.7 ± 14.7 (3-54) idi. OHT sonrası genel sağkalım oranları 1., 3. ve 5. yılda sırasıyla %92.6, %77.6 ve %69.4 idi. İzlemde dekompanze kalp yetmezliği ile başvuran ve pulse steroid + plazmaferez uygulanan hastaların plazmaferez sonrası 1., 3. ve 5. yılda sağkalım oranları sırasıyla %70.4, %58.8 ve %53.4 idi. Nakil sonrası median rejeksiyon süresi 19 aydı (0-113 ay). Tedavi öncesi ve sonrası sol ventrikül ejeksiyon fraksiyonları sırasıyla %25.11±%11.1 ve %52.14±%13.4 idi (p<0.05). Mortalitenin önde gelen nedeni ise sepsise neden olan pnömoni (5/13 hasta) idi. Sonuç: EMB'nin yapılmasının mümkün olmadığı dekompanze kalp yetmezliği olan akut rejeksiyon hastalarında, IV pulse steroid tedavisine ek olarak plazmaferez uygulanması sağkalımı olumlu etkileyebilir.
- 31 December 2022
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 32 (6) , 719-723
Open AccessKalp Nakli Sonrası Dekompanze Kalp Yetmezliğine Neden Olan Akut Rejeksiyonda Plazmaferezin Rolü
Background/Aims: In this study, the results of patients who had orthotopic heart transplantation (OHT) in acute rejection who admitted to our clinic with decompensated heart failure and who could not undergo endomyocardial biopsy (EMB) were evaluated. Methods: The study included 27 patients who underwent OHT in our clinic between December 1998 and November 2021, who admitted with acute rejection causing decompensated heart failure during follow-up, and who could not undergo EMB and administered IV pulse steroid plus plasmapheresis. Demographics of patients, peri-treatment left ventricular functions, survival rates and causes of mortality were analyzed. Results: 19 (70.4%) were male and mean age was 28.7 ± 14.7 (range: 3-54). After OHT, overall survival rates were 92.6%, 77.6%, and 69.4% at 1st, 3rd and 5th year respectively. During the follow-up, the survival rates of patients who presented with decompensated heart failure and given pulse steroid plus plasmapheresis were 70.4%, 58.8%, and 53.4% at 1st, 3rd and 5th year respectively after plasmapheresis. Median rejection time after transplant was 19 months (range 0-113 months). Pre-, and post-treatment left ventricle ejection fractions were 25.11% ± 11.1%, and 52.14% ± 13.4% respectively (p<0.05). The leading causes of mortality were pneumonia causing sepsis (5/13 patients). Conclusions: In acute rejection patients with decompensated heart failure in whom EMB is not possible, administration of plasmapheresis in addition to IV pulse steroid therapy may have a positive effect on survival in this patient group. Özet Amaç: Bu çalışmada ortotopik kalp nakli (OHT) yapılan, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile kliniğimize başvuran ve endomiyokardiyal biyopsi (EMB) yapılamayan hastaların sonuçları değerlendirildi. Yöntemler: Çalışmaya Aralık 1998-Kasım 2021 tarihleri arasında kliniğimizde OHT yapılıp, takip sırasında dekompanze kalp yetmezliğine neden olan akut rejeksiyon ile başvuran ve EMB uygulanamayan, IV pulse steroid + plazmaferez uygulanan 27 hasta dahil edildi. Hastaların demografik özellikleri, tedavi öncesi sol ventrikül fonksiyonları, sağkalım oranları ve mortalite nedenleri analiz edildi. Bulgular: Hastaların 19'u (%70.4) erkekti ve yaş ortalaması 28.7 ± 14.7 (3-54) idi. OHT sonrası genel sağkalım oranları 1., 3. ve 5. yılda sırasıyla %92.6, %77.6 ve %69.4 idi. İzlemde dekompanze kalp yetmezliği ile başvuran ve pulse steroid + plazmaferez uygulanan hastaların plazmaferez sonrası 1., 3. ve 5. yılda sağkalım oranları sırasıyla %70.4, %58.8 ve %53.4 idi. Nakil sonrası median rejeksiyon süresi 19 aydı (0-113 ay). Tedavi öncesi ve sonrası sol ventrikül ejeksiyon fraksiyonları sırasıyla %25.11±%11.1 ve %52.14±%13.4 idi (p<0.05). Mortalitenin önde gelen nedeni ise sepsise neden olan pnömoni (5/13 hasta) idi. Sonuç: EMB'nin yapılmasının mümkün olmadığı dekompanze kalp yetmezliği olan akut rejeksiyon hastalarında, IV pulse steroid tedavisine ek olarak plazmaferez uygulanması sağkalımı olumlu etkileyebilir.